Literature DB >> 2009567

Angiographic follow-up and clinical outcome of 126 patients after percutaneous directional atherectomy (Simpson AtheroCath) for occlusive peripheral vascular disease.

G Dorros1, S Iyer, R Lewin, R Zaitoun, L Mathiak, K Olson.   

Abstract

Angiographic and clinical follow-up data were obtained in 115/126 patients who underwent directional atherectomy for peripheral vascular disease; of the 126, ten were excluded for appropriate reasons and one was lost to follow-up. Thus, 115/116 successful atherectomy patients (99%) had follow-up of 182/213 lesions (86%): 74 patients (64%) with angiography (mean time 5.4 mon), and 41 patients (36%) clinically. One hundred twenty-eight of 183 lesions (70%) had angiographic follow-up; the lesion recurrence as a stenosis or as an occlusion was 53%. Lesion distribution did not differ between angiography and clinical follow-up groups: nearly 85% were within the superficial femoral or popliteal arteries. Despite data stratification, angiographic follow-up indicated that patients after successful directional atherectomy, at a mean follow-up time of 5 mos, have more than a 50% lesion recurrence rate. Although directional atherectomy (Simpson AtheroCath) utilizing present techniques has excellent primary success and acceptable complication rates, angiographic follow-up statistics are bothersome.

Entities:  

Mesh:

Year:  1991        PMID: 2009567     DOI: 10.1002/ccd.1810220202

Source DB:  PubMed          Journal:  Cathet Cardiovasc Diagn        ISSN: 0098-6569


  2 in total

1.  Evaluation of the pullback atherectomy catheter in the treatment of lower limb vascular disease.

Authors:  S Grubnic; S D Heenan; T M Buckenham; A M Belli
Journal:  Cardiovasc Intervent Radiol       Date:  1996 May-Jun       Impact factor: 2.740

Review 2.  [Percutaneous mechanical atherectomy for treatment of peripheral arterial occlusive disease].

Authors:  A Buecker; P Minko; A Massmann; M Katoh
Journal:  Radiologe       Date:  2010-01       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.